Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Drug Utilization in Korean Children with Kawasaki Disease

국내 가와사키병 환아의 약물사용

  • Cha, SungHee (College of Pharmacy, Pusan National University) ;
  • Je, Nam Kyung (College of Pharmacy, Pusan National University)
  • Received : 2017.08.30
  • Accepted : 2017.09.22
  • Published : 2017.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Kawasaki disease (KD) is an acute febrile, systemic vasculitis as a leading cause of acquired heart disease in children. Intravenous immunoglobulin G (IVIG) and aspirin are the standard initial therapy in the treatment of acute KD. The purpose of this study was to investigate drug utilization in children with KD, and to compare "IVIG + high-dose aspirin" and "IVIG + moderate-dose aspirin" in preventing cardiac complications. Methods: We analyzed pediatric patient sample data compiled by the Health Insurance Review & Assessment Service from 2010 to 2015. We identified patients with KD using the KCD-6 code of M30.3. We excluded patients in chronic phase or ${\geq}1$0 years. We also excluded patients who were diagnosed KD in November or December. Drug utilization pattern were assessed in acute KD patients and 30-day and 60-day cardiac complications were investigated between "IVIG + high-dose aspirin" group and "IVIG + moderate-dose aspirin" group. Results: In acute phase, IVIG was administered to 95.8% patients, and 57.1% patients were prescribed moderate-dose aspirin and 25% patients were with high-dose aspirin. Steroid use was rapidly increased from 4.0% in 2010 to 11.3% in 2015. Both 30-day and 60-day cardiac complications occurred less in "IVIG + high-dose aspirin" group compared to "IVIG + moderate-dose aspirin" group, but not statistically significant (0.9% vs 1.8%, p=0.252 for 30-day complication rate; 1.5% vs 2.7%. p=0.073 for 60-day complication rate). Conclusion: We were not able to demonstrate which aspirin therapy is superior for preventing cardiac complications in acute KD patients and further research is warranted.

Keywords

References

  1. Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol 2012;22:79-85. https://doi.org/10.2188/jea.JE20110131
  2. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71. https://doi.org/10.1161/01.CIR.0000145143.19711.78
  3. Abe J, Ebata R, Jibiki T, et al. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol 2008;122:1008-13.e8. https://doi.org/10.1016/j.jaci.2008.09.011
  4. Park YW, Han JW, Hong YM, et al. Epidemiological features of Kawasaki disease in Korea, 2006-2008. Pediatr Int 2011;53:36-9. https://doi.org/10.1111/j.1442-200X.2010.03178.x
  5. Kim GB, Park S, Eun LY, et al. Epidemiology and Clinical Features of Kawasaki Disease in South Korea, 2012-2014. Pediatr Infect Dis J 2017;36:482-5. https://doi.org/10.1097/INF.0000000000001474
  6. Research Committee of the Japanese Society of Pediatric C, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki D. Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version). Pediatr Int 2014;56:135-58. https://doi.org/10.1111/ped.12317
  7. Zhou C, Huang M, Xie L, Shen J, Xiao T, Wang R. IVIG inhibits TNFalpha-induced MMP9 expression and activity in monocytes by suppressing NF-kappaB and P38 MAPK activation. Int J Clin Exp Pathol 2015;8:15879-86.
  8. Matsuda A, Morita H, Unno H, et al. Anti-inflammatory effects of high-dose IgG on TNF-alpha-activated human coronary artery endothelial cells. Eur J Immunol 2012;42:2121-31. https://doi.org/10.1002/eji.201242398
  9. Durongpisitkul K, Gururaj VJ. The prevention of coronary artery aneurysm in Kawasaki disease: A meta-analysis on the efficacy. Pediatrics 1995;96:1057.
  10. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93. https://doi.org/10.1016/S0022-3476(97)70038-6
  11. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017;135:e927-e99. https://doi.org/10.1161/CIR.0000000000000484
  12. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
  13. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blindedendpoints trial. Lancet 2012;379:1613-20. https://doi.org/10.1016/S0140-6736(11)61930-2
  14. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
  15. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237-40. https://doi.org/10.1016/j.jpeds.2006.03.050
  16. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131-7.
  17. Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9. https://doi.org/10.1016/S0022-3476(05)80972-2
  18. Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31:808-10.
  19. Tremoulet AH, Pancoast P, Franco A, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012;161:506-12.e1. https://doi.org/10.1016/j.jpeds.2012.02.048
  20. Akagi T, Kato H, Inoue O, et al. Salicylate treatment in Kawasaki disease: high dose or low dose? Eur J Pediatr 1991;150:642-6. https://doi.org/10.1007/BF02072625
  21. Saguil A, Fargo M, Grogan S. Diagnosis and management of kawasaki disease. Am Fam Physician 2015;91:365-71.
  22. Park YW, Park IS, Kim CH, et al. Epidemiologic study of Kawasaki disease in Korea, 1997-1999: comparison with previous studies during 1991-1996. J Korean Med Sci 2002;17:453-6. https://doi.org/10.3346/jkms.2002.17.4.453
  23. Park YW, Han JW, Park IS, et al. Epidemiologic picture of Kawasaki disease in Korea, 2000-2002. Pediatr Int 2005;47:382-7. https://doi.org/10.1111/j.1442-200x.2005.02079.x
  24. Ha S, Seo GH, Kim KY, et al. Epidemiologic Study on Kawasaki Disease in Korea, 2007-2014: Based on Health Insurance Review & Assessment Service Claims. J Korean Med Sci 2016;31:1445-9. https://doi.org/10.3346/jkms.2016.31.9.1445
  25. Kuo HC, Lo MH, Hsieh KS, et al. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease. PLoS One 2015;10:e0144603. https://doi.org/10.1371/journal.pone.0144603
  26. Baumer JH, Love SJ, Gupta A, et al. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006:Cd004175.
  27. Hamada H. Aspirin treatment for patients with Kawasaki disease. Nihon Rinsho 2014;72:1612-6.